Journal of Clinical Endocrinology & Metabolism, Vol 68, 499-504, Copyright © 1989 by Endocrine Society

ARTICLES

Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion

DE Moller, AC Moses, K Jones, MO Thorner and ML Vance
Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215.

Two patients with acromegaly secondary to ectopic GHRH secretion by metastatic carcinoid tumors were studied before and during therapy with the somatostatin analog octreotide (SMS 201-995). GH and GHRH secretory patterns were assessed during intermittent sc administration, continuous sc infusion (CSI), and continuous iv infusion of octreotide. Octreotide reduced serum GH and plasma GHRH levels in the two patients, although there was differential sensitivity of GH and GHRH. Intermittent sc therapy transiently lowered serum GH in both patients. A higher iv dose was required to reduce plasma GHRH by 50% than to reduce serum GH by 50% (2.0 vs. 0.05 micrograms/kg.h, respectively; patient 1). A similar pattern was found during CSI octreotide administration in the same patient. Chronic therapy with intermittent sc and CSI octreotide was assessed by serial 24-h profiles of GH and GHRH secretion in patient 2. Mean hourly serum GH levels decreased from a pretreatment level of 31.5 +/- 3.5 (+/- SE) to 9.5 +/- 1.5 micrograms/L during CSI therapy (1000 micrograms/day or 0.40 micrograms/kg.h). In contrast, plasma GHRH levels were less effectively suppressed. The mean serum GH levels and the variation in hourly GH values were reduced to a greater extent with CSI than with intermittent sc therapy. Serum insulin-like growth factor I also declined from 5.9 x 10(3) to 2.5 x 10(3) U/L during chronic CSI therapy (patient 2). CSI therapy with octreotide can be more effective than intermittent sc therapy in controlling GH excess in the rare syndrome of ectopic GHRH secretion, although serum GH may not decline to normal.

This article has been cited by other articles:

				M. C. Zatelli, P. Maffei, D. Piccin, C. Martini, F. Rea, D. Rubello, A. Margutti, M. D. Culler, N. Sicolo, and E. C. d. Uberti Somatostatin Analogs in Vitro Effects in a Growth Hormone-Releasing Hormone-Secreting Bronchial Carcinoid J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2104 - 2109. [Abstract] [Full Text] [PDF]

				A. Van den Bruel, J. Fevery, J. Van Dorpe, L. Hofland, and R. Bouillon Hormonal and Volumetric Long Term Control of a Growth Hormone-Releasing Hormone-Producing Carcinoid Tumor J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3162 - 3169. [Full Text]

				M. R. Drange and S. Melmed Long-Acting Lanreotide Induces Clinical and Biochemical Remission of Acromegaly Caused by Disseminated Growth Hormone-Releasing Hormone-Secreting Carcinoid J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3104 - 3109. [Abstract] [Full Text]

				C. A. Jaffe, R. DeMott-Friberg, L. A. Frohman, and A. L. Barkan Suppression of Growth Hormone (GH) Hypersecretion due to Ectopic GH-Releasing Hormone (GHRH) by a Selective GHRH Antagonist J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 634 - 637. [Abstract] [Full Text] [PDF]